PCRX — Pacira BioSciences, Inc.

Summary of PCRX Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• EXPAREL Net Sales: Increased to $143.3 million, up from $136.5 million YoY, driven by a 7% volume growth, although impacted by a shift in vial mix and winter storms.
• ZILRETTA Sales: Rose 15% to $26.8 million from $23.3 million in Q1 2025.
• ioverao Sales: Increased 21% to $6.2 million compared to $5.1 million in Q1 2025.
• Gross Margin: Non-GAAP gross margin was 80%, slightly down from 81% YoY.
• Adjusted EBITDA: Approximately $40.2 million for the quarter.
• R&D Expenses: Increased to $25.4 million from $23.1 million YoY, reflecting ongoing clinical studies.
• SG&A Expenses: Increased to $83.9 million from $76.2 million YoY, influenced by proxy-related costs.
• Share Repurchases: $50 million executed, reducing share count by approximately 2.2 million shares.

2. Strategic Updates and Business Highlights

• Five by 30 Strategy: One year into the strategy, the company reports progress across five key goals: patients served, product revenue, profitability, pipeline, and partnerships.
• EXPAREL Growth: Continued growth attributed to expanded Medicare coverage, new billing codes, and increased awareness of opioid-sparing programs.
• ZILRETTA and ioverao: Both products are seeing strong performance due to dedicated sales forces and strategic partnerships, notably with Johnson & Johnson MedTech.
• Pipeline Developments: Advancements in clinical-stage assets, including PCRX201 (gene therapy for knee OA) and PCRX2002 (hydrogel formulation for postsurgical pain), with key data readouts expected later in the year.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Total revenues expected between $745 million and $770 million, with EXPAREL sales projected at $600 million to $620 million.
• R&D and SG&A Expenses: Non-GAAP R&D expenses anticipated between $105 million and $115 million, while SG&A expenses are expected to be between $320 million and $340 million.
• Gross Margins: Expected to range from 77% to 79%, with potential fluctuations in Q4 due to inventory costs.

4. Bad News, Challenges, or Points of Concern

• Winter Storm Impact: The winter storms affected shipping and procedure scheduling, leading to potential revenue loss and rescheduling of surgeries.
• SG&A Expense Increases: Elevated SG&A expenses due to proxy-related activities and legal fees recovery from the previous year may not reflect normalized spending.
• NOPAIN Act Expiration: The NOPAIN Act is set to expire in 2027, raising concerns about future reimbursement policies and coverage.

5. Notable Q&A Insights

• R&D Spending Cadence: Expected increase in Q2 followed by a decrease in Q3 and Q4 as clinical studies progress.
• Elective Procedure Trends: Elective procedures are up mid-single digits, but overall market trends remain flat year-over-year.
• Competitive Landscape: Questions raised regarding emerging therapies for knee OA and how PCRX201 will differentiate itself in a competitive market.
• Ex-U.S. Partnerships: The company is pursuing international partnerships, with potential revenue implications still in early stages.

Overall, Pacira BioSciences reported solid financial results for Q1 2026, demonstrating progress in its strategic initiatives while facing challenges related to external market conditions and cost management. The company remains optimistic about its growth trajectory and pipeline advancements.